Hua33 (Not yet branded)
Other Medications
Description
Hua33 is a humanized monoclonal antibody that targets the A33 antigen, a glycoprotein highly expressed on the surface of colorectal cancer cells. This targeted therapy is designed specifically for patients with metastatic colorectal cancer and has been evaluated in combination with chemotherapy agents like capecitabine. The antibody can be conjugated with radioactive iodine-131 to create a radioimmunotherapy approach for enhanced tumor targeting.
Mechanism of Action
Hua33 binds specifically to the A33 antigen, which is abundantly expressed on normal intestinal epithelium and colorectal carcinomas but has limited expression in other tissues. When conjugated with 131I, the antibody delivers targeted radiation directly to tumor cells expressing the A33 antigen, causing localized DNA damage and cell death while minimizing systemic toxicity.
Molecular Targets
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
Quick Info
| Brand Name | Not yet branded |
| Category | Other Medications |
 Status | Experimental |
 EMA Status | Experimental |
 Spain Access | Not available |
| Administration | IV |
| Clinical Trials | 2 |
Related Medications
Medical Disclaimer
This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.